AG-881

allosteric mutant IDH1/2 dual inhibitor

oral, brain penetrant, completed Ph. I in HV

from SBDD of prior mIDH inhibitor

ACS Med. Chem. Lett., 2020, 11, 101-107

Agios Pharmaceuticals, Cambridge, MA

AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.